Here are three things to know.
1. The drugmaker will now offer a 0.3 milligram prefilled syringe of Lucentis to treat diabetic macular edema and diabetic retinopathy.
2. Lucentis is intended to be injected once a month by a healthcare professional and used along with good diabetic blood sugar control.
3. Genentech expects the Lucentis 0.3 milligram prefilled syringe to hit the market in the second quarter of 2018.
Editor’s note: This article was updated March 23 at 8:00 am.
More articles on supply chain:
Survey: Top healthcare supply chain priorities in 2018
Trump: Stay tuned for federal action on high drug prices
Intermountain, SSM, Ascension and Trinity’s generic drug venture could have a third of the hospital market as members: 6 things to know
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
